Jan Kern, Judith Böhringer, Dagmar Timmann, Regina Trollmann, Claudia Stendel, Cristoph Kamm, Markus Röbl, Vidiyaah Santhanakumaran, Samuel Groeschel, Stefanie Beck-Wödl, Sophia Göricke, Ingeborg Krägeloh-Mann, Matthis Synofzik
BACKGROUND AND OBJECTIVES: GM2 gangliosidoses, a group of autosomal-recessive neurodegenerative lysosomal storage disorders, result from β-hexosaminidase (HEX) deficiency with GM2 ganglioside as its main substrate. Historically, GM2 gangliosidoses have been classified into infantile, juvenile, and late-onset forms. With disease-modifying treatment trials now on the horizon, a more fine-grained understanding of the disease course is needed. METHODS: We aimed to map and stratify the clinical course of GM2 gangliosidoses in a multicenter cohort of pediatric and adult patients...
January 9, 2024: Neurology